Histopathological risk factors for malignancy in dermatomyositis

被引:5
|
作者
Pruessmann, Wiebke [1 ]
Kleinheinz, Andreas [2 ]
Zillikens, Detlef [1 ]
Rose, Christian [1 ,3 ]
机构
[1] Univ Lubeck, Dept Dermatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany
[2] Dermatopathol Lubeck, Lubeck, Germany
[3] Clin Ctr Buxtehude, Dept Dermatol, Buxtehude, Germany
关键词
dermatomyositis; malignant neoplasms; histopathological risk factors; basement membrane thickening; pigment incontinence; CD123+plasmacytoid dendritic cells; eosinophils; PLASMACYTOID DENDRITIC CELLS; POLYMYOSITIS; EOSINOPHILS; DISTINCT;
D O I
10.1111/his.14727
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To identify possible histopathological risk factors for malignancy in skin biopsies of dermatomyositis patients. Methods and results: We analysed clinical metadata and studied 30 skin biopsies of 11 patients with and 12 patients without associated malignancy, who were treated in one secondary and one tertiary German medical centre between 2009 and 2022 and fulfilling the EULAR/ACR classification criteria for dermatomyositis. Specimens were categorized by malignancy status and evaluated based on haematoxylin and eosin (H&E), periodic acid Schiff (PAS), Alcian Blue, and anti-CD123 immunohistochemistry stains. After correcting for multiple testing, biopsies of patients with cancer exhibited more severe basement membrane thickening (P < 0.05) and pigment incontinence (P < 0.05) compared to patients without tumour burden. Patients with numerous subepidermal melanophages had a more than 5-times increased odds ratio to suffer from an internal malignancy (odds ratio [OR] 5.3, 95% confidence interval [CI] 1.3-54.2, P < 0.05). Furthermore, specimens of the malignancy group presented a distinct superficial distribution pattern of CD123+ plasmacytoid dendritic cells (PDCs, P < 0.01). Extravascular eosinophils were absent in all cases. Conclusion: Severity of basement membrane thickening, extent of pigment incontinence, and superficial distribution pattern of CD123+ PDCs could serve as useful histopathological indicators of risk for malignancy in dermatomyositis.
引用
收藏
页码:529 / 535
页数:7
相关论文
共 50 条
  • [1] Polymyositis/dermatomyositis and Malignancy Risk: A Metaanalysis Study
    Yang, Zaixing
    Lin, Feng
    Qin, Baodong
    Liang, Yan
    Zhong, Renqian
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (02) : 282 - 291
  • [2] Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis
    Marzecka, Milena
    Niemczyk, Anna
    Rudnicka, Lidia
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2022, 63 (02) : 289 - 296
  • [3] Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?
    Khanna, Urmi
    Galimberti, Fabrizio
    Li, Yumeng
    Fernandez, Anthony P.
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
  • [4] Clinical and biological factors predictive of malignancy in dermatomyositis
    Prohic, A.
    Kasumagic-Halilovic, E.
    Simic, D.
    Selmanagic, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (05) : 591 - 592
  • [5] Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study
    Chen, YJ
    Wu, CY
    Shen, JL
    BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (04) : 825 - 831
  • [6] Risk of Malignancy in Dermatomyositis and Polymyositis: A Systematic Review and Meta-Analysis
    Qiang, Judy K.
    Kim, Whan B.
    Baibergenova, Akerke
    Alhusayen, Raed
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2017, 21 (02) : 131 - 136
  • [7] The Characteristics and Risk Factors of Cytomegalovirus Infection in Dermatomyositis
    Zhang, Min
    Yan, Bing
    INDIAN JOURNAL OF MICROBIOLOGY, 2024,
  • [8] Dermatomyositis and malignancy
    Hu, Tina
    Vinik, Ophir
    CANADIAN FAMILY PHYSICIAN, 2019, 65 (06) : 409 - 411
  • [9] Janus kinase inhibitors and risk of internal malignancy in dermatomyositis
    Ji-Xu, Antonio
    Le, Stephanie T.
    Maverakis, Emanual
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (06) : 2881 - 2882
  • [10] Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis
    Milena Marzęcka
    Anna Niemczyk
    Lidia Rudnicka
    Clinical Reviews in Allergy & Immunology, 2022, 63 : 289 - 296